SCHEMBL2834778

SCHEMBL2834778

CNCc1nc(-c2ccccc2)n(Cc2ccc(F)cc2)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
TP53 P04637 2/20 0.43
LMNA P02545 4/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PDE6D O43924 1/20 0.41
ALDH2 P05091 1/20 0.41
ALDH3A1 P30838 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP2D6 P10635 1/20 0.40
CHRM1 P11229 1/20 0.40
HRH1 P35367 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RAB9A P51151 2/20 0.40
CYP11B2 P19099 2/20 0.39
CYP11B1 P15538 1/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL2838926 0.94 ALDH1A1 (0.44) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL2836740 0.73 CYP11B1 (0.46) ALDH1A1KDM4EGAATP53LMNA
Hydrochloric Acid SCHEMBL2835333 0.72 CYP11B1 (0.45) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL11099962 0.72 ALDH1A1 (0.49) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL2838929 0.71 KDM4E (0.38) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL8957207 0.69 ALDH1A1 (0.49) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL11105634 0.68 KDM4E (0.39) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL6967064 0.68 ALDH1A1 (0.51) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL11254294 0.67 ALDH1A1 (0.46) ALDH1A1KDM4EGAATP53LMNA
SCHEMBL28261635 0.66 ALDH1A1 (0.72) ALDH1A1KDM4EGAATP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP claimed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US claimed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP claimed
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R ALDH1A1 2505/4885KDM4E 1514/4885GAA 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.